Business Context and Reporting Period
Company: ADC Therapeutics SA (ADCT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: ADC Therapeutics is a commercial-stage global pioneer in antibody drug conjugates (ADCs). Its flagship product, ZYNLONTA (loncastuximab tesirine), is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the U.S., Europe, and China. The company is advancing ZYNLONTA into earlier lines of therapy and other indications (e.g., follicular lymphoma, marginal zone lymphoma) while developing a pipeline of early-stage solid tumor ADCs.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Total Revenue | $70.8 million | $69.6 million |
| Product Revenue (Net) | $69.3 million | $69.1 million |
| License Revenue & Royalties | $1.6 million | $0.5 million |
| Net Loss | $(157.8) million | $(240.1) million |
| Loss Per Share (Basic & Diluted) | $(1.62) | $(2.94) |
| Cash and Cash Equivalents | $250.9 million | $278.6 million |
| Accumulated Deficit | $(1,493.3) million | $(1,335.5) million |
| Deferred Royalty Obligation (Long-term) | $320.1 million | $303.6 million |
| Senior Secured Term Loans | $113.6 million | $112.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 1.8% to $70.8 million, driven primarily by a 212.7% increase in license revenues and royalties ($1.6 million vs. $0.5 million) due to royalties from the Sobi agreement. Product revenue remained relatively flat ($69.3 million vs. $69.1 million) due to higher selling prices offset by lower sales volume.
- Expense Reduction: Total operating expenses decreased 14.5% to $201.5 million.
- R&D Expenses: Decreased 13.8% to $109.6 million, largely due to reduced spending on discontinued programs (Cami, ADCT-901, ADCT-212) and lower costs for the ZYNLONTA program.
- Selling & Marketing: Decreased 23.4% to $44.0 million, driven by a $12.0 million reduction in marketing and advertising expenses and lower employee headcount.
- Cost of Product Sales: Increased 135.2% to $5.9 million due to higher stability/shipping costs, a batch cancellation fee, and expensing of commercial inventory for CMO validation.
- Net Loss Improvement: Net loss narrowed by 34.2% to $157.8 million, reflecting lower operating expenses and a significant reduction in income tax expense (from $39.1 million in 2023 to $0.2 million in 2024).
- Financing Activity: The company raised approximately $97.4 million in net proceeds from an underwritten equity offering in May 2024.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Catalysts:
- LOTIS-5: Enrollment completed in 2024 for the Phase 3 confirmatory trial of ZYNLONTA + rituximab in 2L DLBCL. Success is critical for maintaining FDA accelerated approval and expanding the label.
- LOTIS-7: Preliminary data (Dec 2024) showed a 94% overall response rate (ORR) for ZYNLONTA + glofitamab in 2L DLBCL. Full enrollment of the dose expansion arm is expected in H1 2025.
- IITs: Strong data presented at ASH 2024 for ZYNLONTA in Marginal Zone Lymphoma (91% ORR) and Follicular Lymphoma (97% ORR).
- Liquidity: Management believes cash resources ($250.9 million) are sufficient to fund operations for at least the next 12 months. The company maintains a $100 million at-the-market (ATM) offering program but has not sold shares under it yet.
- Key Risks:
- Debt Covenants: The company has a $120 million senior secured term loan (maturing 2029) with a revenue covenant requiring minimum U.S. ZYNLONTA net sales if market cap is below $650 million. It also has a deferred royalty obligation to HealthCare Royalty Partners (HCR) capped at 2.5x the investment amount ($750 million).
- Regulatory: Continued approval of ZYNLONTA is contingent on the success of the LOTIS-5 confirmatory trial. Failure could result in withdrawal of the product.
- Manufacturing: Reliance on third-party CMOs for all manufacturing; supply chain disruptions or quality issues could impact sales.
- Unusual Items:
- Income Tax: The 2023 tax expense included a $37.1 million deferred tax expense due to a change in intercompany transfer pricing. This non-recurring item significantly impacted the prior year's loss.
- Deferred Royalty Adjustment: A $11.2 million cumulative catch-up adjustment income was recorded in "Other, net" in 2024 due to revised revenue forecasts affecting the HCR obligation valuation.
Investor Verification Checklist
- LOTIS-5 Trial Status: Verify the timeline for data readout and the specific endpoints required to confirm clinical benefit for the 2L DLBCL indication.
- Debt Covenant Compliance: Monitor quarterly U.S. net sales of ZYNLONTA to ensure compliance with the revenue covenant in the Loan Agreement, given the company's market capitalization.
- HCR Royalty Obligation: Review the assumptions used in the Monte Carlo simulation for the deferred royalty liability, as changes in revenue forecasts can cause significant volatility in "Other, net" income/expense.
- Manufacturing Supply: Confirm the status of the new CMO facility validation and any potential supply constraints for ZYNLONTA.
- Discontinued Programs: Assess the impact of the discontinuation of ADCT-601 (Nov 2024) and other programs on the future R&D pipeline and cash burn rate.